The ongoing litigation in the U.S. over CRISPR-Cas9 patents could be resolved this year, but it will take longer to get a clear picture of the global CRISPR IP landscape. It is possible that companies seeking to use the technology will have to obtain licenses from different patent holders to operate in different regions, and a new set of controversies could erupt over other CRISPR nucleases.
Following April 30 oral arguments at the U.S. Court of Appeals for the Federal Circuit (CAFC), a decision in patent litigation pitting the Regents of the University of California against the Broad Institute of MIT and Harvard is expected by the fall.
While the battle over ownership of foundational CRISPR-Cas9 patents may be drawing to a close in Washington, related but separate skirmishes in Europe could continue for years.
In its briefs and